BioSpace News Archive

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Mel Hayes as Chief Commercial Officer, effective September 7, 2021.

Recro Pharma, Inc. and BioCorRx, Inc. announced the expansion of the companies’ ongoing relationship with the signing of a new development and manufacturing agreement.

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk-based fibers, announces that it is now rearing the second generation of silkworms at the new production headquarters for Prodigy Textiles, the Company’s Vietnamese subsidiary.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $116 million Series B financing.

Bolt Biotherapeutics, Inc. today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics’ BDC-1001 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® (nivolumab).

Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that Chief Executive Officer David L. Lucchino will present at the following investor conferences.

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), today announced that GastroZentrum Lippe, has enrolled patients into the European Union (EU) outpatient study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021.

Selecta Biosciences, Inc. (NASDAQ: SELB), and Cyrus Biotechnology, Inc., today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics.